---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-020222"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2024-05-16T23:59:59+00:00"
generated_at: "2026-06-01T21:43:01.449683+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Director David LaPre resigns from Calidi Biotherapeutics board

## Summary
- David LaPre resigned as director and from all board committees effective May 10, 2024.
- Resignation not due to any dispute with the company or Board on operations or policies.
- No replacement director has been announced as of the filing date.

## SEC filing metadata
- accession: 0001493152-24-020222
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2024-05-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000149315224020222/0001493152-24-020222-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000149315224020222/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-020222
- JSON: https://secwatch.observer/filing/0001493152-24-020222.json
- Plain text: https://secwatch.observer/filing/0001493152-24-020222.txt

## Key facts
- Executive change
  David LaPre resigned as Director at Calidi Biotherapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On May 10, 2024, Mr. David LaPre notified the Board of Directors (the “Board”) of Calidi Biotherapeutics, Inc. (the “Company”) of his resignation as a director of the Company, including his position on each Board committee on which he served, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000149315224020222/0001493152-24-020222-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.